One platform. Every decision point.
A single, guideline-complete molecular assay that runs on the real-time PCR hardware most labs already own — delivering NGS-class sensitivity and 100% specificity, from tissue or blood.
Accurate. Fast. Agile. Smart.
Sensitivity that beats NGS.
Median LoD₉₅ 0.3% VAF in blood; <3% VAF in tissue. 100% specificity across every guideline gene. In head-to-head validation: 97/100% PPA/NPA vs NGS.
Next-day report.
A clinician-ready result the day after the sample reaches the lab. Reports in as little as 34 hours — even from a QNS sample.
Tissue or blood. One panel.
Same 11-gene guideline-complete panel runs on FFPE tissue or 10 mL of plasma. Repeatable for serial monitoring — turning a snapshot into a molecular timeline.
DNA + RNA together.
Both nucleic acids in a single workflow — every actionable driver, whether it's a mutation or a fusion. Plus resistance intelligence over time.
Five assays. One platform. Every decision point.
Each ONCO X test is a purpose-built application of the same core chemistry — tuned to the indication, the sample type, and the clinical question. All five run on the same QuantStudio™ 5 hardware, so a lab that adopts one can eventually run them all.
PulmoSmart
The workhorse NSCLC panel on FFPE tissue. 11 guideline genes, 114 variants, DNA and RNA together from a single sample. 5–7 day turnaround, 100% specificity, ~1% failure rate versus the ~25% NGS norm. Built for the tissue blocks Indian oncologists actually work with.
PulmoSmart Prime
The same guideline-complete 11-gene NSCLC panel — delivered in 2 days on a fast-track workflow. For fast-progressing disease, fragile patients, and cases where the oncologist needs the molecular answer before the next clinic visit.
LiquiSmart
Ultra-sensitive ctDNA testing from a single 10 mL blood draw. Median LoD₉₅ 0.3% VAF, 100% specificity, 34-hour actionable reports — even from QNS samples that failed NGS. Repeatable for serial monitoring, so resistance becomes visible before imaging shows progression: EGFR T790M/C797S, ALK G1202R, MET and HER2 bypass amplification.
OcuriaSmart
A urine- and tissue-based molecular assay for bladder cancer — designed for both non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) disease. Covers FGFR3, TERT promoter, TP53, PIK3CA and RAS hotspots for early detection, recurrence surveillance and treatment stratification. Same PCR platform, same next-day economics.
ColoSmart
A guideline-complete panel for metastatic colorectal cancer — KRAS, NRAS, BRAF V600E, PIK3CA, HER2 amplification and MSI status in a single reflex-friendly workflow. Designed to answer the anti-EGFR and immunotherapy questions in one run, from FFPE tissue or plasma, on the QuantStudio your lab already runs.
Our own NGS platform — in months.
PCR gives us speed and lab-friendly economics for the tests that matter most, most days. But some indications — deep multi-gene profiling, tumor-informed MRD, comprehensive genomic profiling — need next-generation sequencing depth.
ONCO X is bringing its own NGS platform to Indian oncology in the coming months — engineered for local throughput, local pricing, and the same rigor of clinical validation.
Read the announcementTested in the labs that set the standard.
- Reagents developed under ISO 13485 manufacturing
- Assay clinically validated at a CLIA-certified, CAP-accredited laboratory
- Independently validated by ONCO X for India · NABL accredited laboratory
- Consistent performance across MD Anderson, UPenn, Medical College of Wisconsin & Fred Hutch
- 77 clinical samples analysed across sites — including pleural effusions, FNAs and FNA washes
- Peer-reviewed publications in Frontiers in Oncology, Journal of Liquid Biopsy, and Translational Lung Cancer Research